An alternative disease activity index for patients with systemic lupus erythematosus called the SLE-DAS (Disease Activity Score) has shown similar results to the Lupus Low Disease Activity State ...
Findings showed a higher percentage of participants on obinutuzumab achieved a minimum 4-point improvement in SRI-4 at 52 weeks vs standard therapy. Topline data were announced from a phase 3 trial ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Each one-unit ...
The study highlights differences between patients with systemic lupus erythematosus (SLE) and healthy controls, potentially shedding light on the disease’s underlying mechanisms. A new “multi-omics” ...
Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease ...
– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results